Alerta

用于递送的脂质化合物和脂质纳米颗粒

Resumen de: CN119874554A

本申请公开了一种化合物，结构式如式(I)所示，以及其药学上可接受的盐或其立体异构体，本申请还公开了一种包含上述化合物或其药学上可接受的盐或其立体异构体的纳米颗粒组合物，本申请的纳米颗粒可以高效递送药物、疫苗至细胞内，发挥药物、疫苗的治疗或预防目的。#imgabs0#

一种含有抗氧化剂和siRNA的纳米复合物及其制备方法和应用

Resumen de: CN119868302A

本发明涉及生物医用材料领域，公开了一种含有抗氧化剂和siRNA的纳米复合物及其制备方法和应用。其制备方法包括：以含有氨基的抗氧化剂和含有苯硼酸结构的化合物为原料，在鎓盐类酰胺化偶联剂催化下得到苯硼酸键修饰的抗氧化剂；将苯硼酸键修饰的抗氧化剂和含有邻二酚结构的脂质在有机溶剂中反应，得到抗氧化剂偶联的脂质；将该脂质和阳离子脂质混合，溶于低沸点有机溶剂，再加入含有siRNA MMP9的DEPC水溶液，超声、减压浓缩，得到含有抗氧化剂和siRNA的纳米复合物。本发明所制备的纳米复合物仅使用两种不同功能的脂质通过静电作用，即可实现对siRNA的有效负载，具有制备方法简单、有效成分明确、生物相容性良好等优点等。

一种基于幽门螺杆菌外膜囊泡的纳米疫苗及其制备方法与应用

Resumen de: CN119868526A

本发明属于疫苗制备领域，具体涉及一种基于幽门螺杆菌外膜囊泡的纳米疫苗及其制备方法与应用。本发明以幽门螺杆菌的OMV和LPS为抗原和佐剂，以DMON为载体，然后利用静电相互作用使DMON吸附LPS小分子，再利用脂质体挤出器将幽门螺杆菌OMV均匀包裹在DMON纳米材料表面，得到基于幽门螺杆菌外膜囊泡的纳米疫苗。本发明通过体内外试验证明该纳米疫苗能够被巨噬细胞摄取，促进巨噬细胞的吞噬能力，显著提高巨噬细胞分泌各种免疫细胞因子的水平，能在小鼠体内诱导高水平的抗原特异性体液免疫、黏膜免疫以及Th1/Th2/Th17型细胞免疫应答。

一种白蛋白维替泊芬纳米粒的制备方法及其应用

Resumen de: CN119868544A

本发明涉及生物医药技术领域，尤其涉及一种白蛋白维替泊芬纳米粒的制备方法及其应用。白蛋白维替泊芬纳米粒在治疗肿瘤中的应用；白蛋白维替泊芬纳米粒的制备方法，步骤如下：将白蛋白聚合物水溶液与维替泊芬高速搅拌反应，并通过100kDa超滤管纯化。本发明提供的一种白蛋白维替泊芬纳米粒的制备方法及其应用，制得的白蛋白维替泊芬纳米粒，其仅能明显增加穿过细胞的药物量，进入细胞后维替泊芬的光动力效应还具有抗肿瘤效果。

T细胞的活化/增殖方法

Resumen de: MX2021004357A

The present invention provides: a method which is for the activation and/or proliferation of T cells and includes a step for bringing a T cell-containing cell population into contact with a nucleic acid delivery carrier having a surface to which at least one T cell-activating ligand is added; a method which is for delivering a nucleic acid into a T cell and includes a step for bringing a T cell-containing cell population into contact with (a) a nucleic acid delivery carrier that has a surface to which at least one T cell-activating ligand is added and that contains a nucleic acid therein, or (b) both of at least one T cell-activating ligand and a nucleic acid delivery carrier that has a surface to which a T cell-activating ligand is not added and that contains a nucleic acid therein; and a method for producing a medicament that contains T cells.

用于递送的脂质化合物和脂质纳米颗粒

Resumen de: CN119874553A

本申请公开了一种化合物，结构式如式(I)所示，以及其药学上可接受的盐或其立体异构体，本申请还公开了一种包含上述化合物或其药学上可接受的盐或其立体异构体的纳米颗粒组合物，本申请的纳米颗粒可以高效递送药物、疫苗至细胞内，发挥药物、疫苗的治疗或预防目的。#imgabs0#

一种脂质纳米颗粒及其应用

Resumen de: CN119876277A

本发明提供了一种脂质纳米颗粒及其应用。本申请对脂质材料配方的比例、最优细胞培养及编辑体系、编辑系统Cas9mRNA：sgRNA比例、Cas9mRNA设计优化进行一系列探索，摸索出适合于针对人造血干细胞转染及编辑的系统，本申请在节约成本的同时，可完全替代目前已有的市面转染试剂不能有效转染原代细胞的问题，实现原代细胞内编辑效率的显著提高，进而能在体内得到很好的治疗效果。

一种噻吩取代的氮杂氟硼二吡咯化合物、化合物的纳米颗粒及它们的制备方法和应用

Resumen de: CN119874742A

本发明公开了一种噻吩取代的氮杂氟硼二吡咯化合物、化合物的纳米颗粒及它们的制备方法和应用。本发明设计并合成的噻吩取代的氮杂氟硼二吡咯化合物，噻吩基团的引入可以使氮杂氟硼二吡咯的吸收光谱显著红移，成功红移至810nm近红外区域，更有利于其在生物体内以及光热治疗方面的应用。以该化合物为内核制备的纳米颗粒在局部腹腔给药后可以有效地分布到内脏脂肪组织，选择性地靶向内脏脂肪组织，具有良好的生物相容性和较高的光热转换效率，可以通过调节其浓度和808nm激光功率实现对温度的调控，可用于光热治疗肥胖。

一种用于抑制新生血管生成的自组装多肽及其制备方法和应用

Resumen de: CN119874811A

本发明涉及一种用于抑制新生血管生成的自组装多肽及其制备方法和应用，所述自组装多肽包括疏水单元、组装单元、特异性靶向Tie2受体的多肽和特异性靶向VEGFR2受体的多肽。本发明提供的自组装多肽同时靶向Tie2受体和VEGFR2受体，特异性靶向血管内皮细胞，在亲疏水作用下自组装形成纳米颗粒，经过配受体相互作用后，由纳米颗粒转变为纳米纤维，阻碍VEGF结合VEGFR2和Ang2结合Tie2，实现在新生血管病灶区域的快速富集，抑制内皮细胞迁移，进而抑制血管的生成。

一种雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料及其应用

Resumen de: CN119868303A

本申请公开了一种雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料及其应用，属于纳米材料合成领域。该雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料为纳米级颗粒，呈方块状结构，包括方块状普鲁士蓝纳米颗粒和包覆在普鲁士蓝纳米颗粒外的雷公藤外泌体样纳米囊泡。通过将雷公藤外泌体纳米囊泡PELNVs加入到普鲁士蓝纳米颗粒溶液中混合，将混合后的体系采用物理挤压使其反复通过聚碳酸酯膜制备得到。所得雷公藤外泌体样纳米囊泡修饰的普鲁士蓝纳米材料具备优异的光热转换性能和抗氧化性能，且溶血率保持极低水平，细胞毒性低，用于类风湿关节炎光热治疗，具有优异的光热治疗能力，生物安全性好，应用前景广泛。

一种兽用复方黄芪多糖注射液及其生产工艺

Resumen de: CN119868272A

本发明公开了一种兽用复方黄芪多糖注射液及其生产工艺，属于兽用医药配制品技术领域，包括如下步骤：将黄芪多糖溶解后与复合纳米颗粒复合得到黄芪多糖负载粉末；将表面活性剂和无水乙醇加入液体石蜡中，将分散液边搅拌边加入反应釜中，然后搅拌得到复方黄芪多糖注射液；本发明的生产工艺通过将环糊精制备成载体吸附和封装黄芪多糖，并利用环糊精载体的吸附能力与聚乳酸形成核壳结构，将包覆有纳米硒的聚乳酸负载在环糊精载体内，既阻止了纳米硒在注射液中的团聚，也使黄芪多糖分散性提高，通过将复合纳米颗粒制备成乳液，提高复合纳米颗粒的分散性，乳液形态的注射液更容易被动物吸收，使纳米硒与黄芪多糖产生协同作用，提高动物的抵抗力。

PEDV与TGEV环状RNA二联苗的创制与应用

Resumen de: CN119876208A

本发明公开了PEDV与TGEV环状RNA二联苗的创制与应用。本发明提供的疫苗组合物由PEDV环状RNA疫苗和TGEV环状RNA疫苗组成，其可以同时防治猪流行性腹泻病毒、猪传染性胃肠炎病毒两种传染病，与单苗相比，二联疫苗组合物没有产生免疫干扰现象，疫苗免疫效果没有下降，可以避免多次接种免疫出现的不良反应，具有广泛的应用价值。

一种调控缺血微环境的工程化血小板膜纳米载体及其制备方法

Resumen de: CN119868305A

本发明提供一种调控缺血微环境的工程化血小板膜纳米载体及其制备方法。所述工程化血小板膜纳米载体由纳米颗粒(DY)和形成于所述纳米颗粒(DY)表面的血小板膜组成，其中，所述纳米颗粒(DY)通过长链分子DSPE‑PEG2000‑Arg‑TK‑CY‑09自组装形成，TK表示ROS响应材料硫缩酮键，CY‑09表示抑制NLRP3炎症小体活化及组装的抗炎药物CY‑09，Arg表示产生NO的L‑Arg，DSPE‑PEG2000表示两亲性聚合物。本发明所提供的工程化血小板膜纳米载体(DY@PM)具有较高的稳定性和生物安全性，可靶向病灶部位，多靶点协同调控缺血微环境，在生物医学领域具有广阔的应用前景。

适用于三组分脂质纳米颗粒的脂质化合物及其应用

Resumen de: CN119874800A

本发明涉及药物输送领域，具体涉及一种脂质化合物、包含该脂质化合物的药物组合物及其制剂和应用。将本发明提供的脂质化合物应用于脂质纳米颗粒系统中，可以将传统的四组分脂质纳米颗粒变为三组分脂质纳米颗粒，提高脂质纳米颗粒药物递送系统的制备效率，并同时具有较好的安全性。

POLYNUCLEOTIDE MOLECULE FOR PREVENTING OR TREATING HPV INFECTION-RELATED DISEASES

Resumen de: TW202432572A

The present application relates to the field of biotechnology, specifically to an mRNA vaccine for treating HPV infection related diseases by inducing HPV antigen-specific immune responses.

NANOPARTICLES CAPABLE OF REALIZING CONTROLLED RELEASE OF CARBON MONOXIDE, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2025081381A1

Nanoparticles capable of realizing controlled release of carbon monoxide, and a preparation method therefor and the use thereof. The nanoparticles capable of realizing controlled release of carbon monoxide comprise triiron dodecarbonyl and Croc-PEG that coats triiron dodecarbonyl, wherein Croc-PEG is a condensation product of Croc and MPEG-NH2. The nanoparticles capable of realizing controlled release of carbon monoxide can effectively improve the loading capacity of carbon monoxide, thereby achieving controlled release of carbon monoxide and high-efficiency low-toxicity CO gas therapy.

TREATMENT OF PRIMARY CILIARY DYSKINESIA WITH SYNTHETIC MESSENGER RNA

Resumen de: AU2025202461A1

Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAIl or DNAH5.

PSMA LIGAND TARGETED COMPOUNDS AND USES THEREOF

Resumen de: US2025127935A1

Prostate-specific membrane antigen (PSMA) targeted compounds having formula (I), nanoclusters formed thereof, pharmaceutical compositions comprising a plurality of these compounds, and methods for treating and detecting cancers in a subject are described herein.

DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO

Resumen de: US2025127925A1

Provided herein is chitosan-derivative nanoparticle comprising chitosan functionalized with a cationic amino acid and a hydrophilic polyol; and methods of making and using same, e.g., for gene delivery in vivo.

Self-Assembling Nanoparticles Based On Amphiphilic Peptides

Resumen de: US2025127887A1

The present disclosure relates to a vaccine comprising an amphiphile having the formula S-B-U-H and at least one peptide antigen conjugate having the formula selected from S-E1-A-E2-U-H and H-U-E1-A-E2-S, wherein the amphiphile and/or the at least one peptide antigen conjugate comprises a dendron amplifier. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, an infectious disease, a cardiovascular disease, or a neurodegenerative disease.

PH-RESPONSIVE NANO PARTICLE FOR DELIVERY OF RIBONUCLEOPROTEINS

Resumen de: US2025127921A1

Provided herein are self-assembled nanoparticles (NPs), pharmaceutical compositions containing such NPs and methods of using such NPs. The NPs comprise an amphiphilic copolymer and a ribonucleoprotein (RNP), and optionally ssODN, wherein: the amphiphilic copolymer is a water-soluble block copolymer comprising a poly(C2-3 alkylene glycol) block and an acrylic block comprising a poly(acrylate), poly(methacrylate) or poly(acrylate/methacrylate) block; the acrylic block comprise ester side chains bearing substituted or unsubstituted alkylamine groups; and the RNP, ssODN, and the acrylic block of the amphiphilic copolymer form a core of the self-assembled nanoparticle, and the poly(ethylene glycol) block of the amphiphilic copolymer forms the exterior of the self-assembled nanoparticle.

NUCLEIC ACID-LIPID NANOPARTICLE AND METHOD USING THE SAME

Resumen de: US2025127882A1

A nucleic acid-lipid nanoparticle is provided, which comprises: a nucleic acid molecule and a lipid mixture. The lipid mixture comprises: an ionizable amino lipid present in an amount of 20 mol % to 60 mol %; a phospholipid present in an amount of 5 mol % to 20 mol %; cholesterol present in an amount of 25 mol % to 60 mol %; and a PEGylated lipid present in an amount of 0.2 mol % to 6 mol %. In addition, methods using the aforesaid nucleic acid-lipid nanoparticle are also provided.

METHODS OF LOADING EXTRACELLULAR VESICLES

Resumen de: US2025127919A1

The present disclosure relates to methods of loading an EV with a payload. In some aspects, the payload and the EV are mixed at a specific loading condition (e.g., at the disclosed salt concentrations, loading temperature, loading duration, payload feed concentration, and/or EV feed concentration), such that the amount of the payload that is associated with the exterior surface of the EV is increased. Also provided herein are methods for producing the extracellular vesicles and methods for using the extracellular vesicles to treat diseases or disorders.

Telmisartan Nanosuspension for Therapy of Respiratory Infections and Methods of Making and Using Same

Resumen de: US2025127761A1

A method of inhibiting viral replication of a virus in an individual comprising administering an effective amount of a drug nanosuspension combined with a surfactant, wherein the drug nanosuspension combined with the surfactant is delivered to the individual's lungs. Preferably, the drug is a nanosuspension delivered to the individual's lungs through inhalation.

HYPERACTIVATING LIPID NANOPARTICLES

Nº publicación: US2025127868A1 24/04/2025

Solicitante:

CORNER THERAPEUTICS INC [US]
Corner Therapeutics, Inc

Resumen de: US2025127868A1

The present disclosure relates to lipid nanoparticles comprising a lysophosphatidylcholine (LPC) compound and at least one further lipid, and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells. The present disclosure also relates to compositions comprising lipid nanoparticles comprising a LPC and at least on further lipid, in which the compositions comprise one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.